|Assessment Status||Rapid review complete|
|Indication||For the treatment of children and adolescents from three years of age with growth disturbance due to insufficient secretion of growth hormone|
|Rapid review commissioned||15/02/2022|
|Rapid review completed||25/03/2022|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that somatrogon be considered for reimbursement*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement – November 2022.